Ivo Meinhold-Heerlein

from Wikipedia, the free encyclopedia

Ivo Meinhold-Heerlein (born March 23, 1969 in Mainz ) is a German gynecologist and obstetrician and university professor . Since April 2018 he has been the director of the Clinic for Gynecology and Obstetrics at the University Hospital Giessen . He is known for his work in the field of molecular characterization of ovarian cancer .

Life

Meinhold-Heerlein studied human medicine from 1989 to 1996 at the Medical University of Lübeck and the Albert Ludwig University of Freiburg . He received his doctorate with the topic "Establishing the technology of non-radioactive in-situ hybridization in normal tissue using the example of human skin" in Freiburg. From 1999 to 2001 he worked as a postdoctoral fellow at The Burnham Institute / La Jolla Cancer Research Center, San Diego, USA. From 2002 to 2007 he was a research assistant and assistant doctor in the Clinic for Gynecology and Obstetrics at the University Medical Center Schleswig-Holstein - Campus Kiel. In 2006 Meinhold-Heerlein was recognized as a specialist in gynecology and obstetrics. In 2007 he completed his habilitation at the Christian-Albrechts-Universität Kiel with the topic: "Mechanisms for overcoming apoptosis resistance and identifying new molecular markers of ovarian cancer ". In the same year he was appointed private lecturer at the Christian-Albrechts University in Kiel. From 2006 to 2008 he was Deputy Head of the Kiel School of Gynecological Endoscopy at the Clinic for Gynecology and Obstetrics at the University Medical Center Schleswig-Holstein - Campus Kiel and received the MIC III certificate from the Gynecological Endoscopy Working Group in 2008 as a laparoscopic surgeon. In 2007 he was appointed senior physician at the Clinic for Gynecology and Obstetrics at the University Medical Center Schleswig-Holstein - Campus Kiel. In 2009 Meinhold-Heerlein became Deputy Director of the Clinic for Gynecology and Obstetrics at the University Hospital Aachen. In the same year he received the specialty title "Special Obstetrics and Perinatal Medicine". In 2012 he was appointed adjunct professor at the Medical Faculty of RWTH Aachen University. In 2013 he received the specialty title "Gynecological Oncology". In 2014 Meinhold-Heerlein was appointed Associate Honorary Professor at the University of Cape Town . In 2015 he was acting director of the Clinic for Gynecology and Obstetrics at the RWTH Aachen University Hospital. He is currently Deputy Director of the Clinic for Gynecology and Obstetrics at the RWTH Aachen University Hospital and head of the Gynecological Cancer Center and the Endometriosis Center at the RWTH Aachen University Hospital. In 2017 he was offered a professorship for gynecological oncology at RWTH Aachen University. Since April 2018 he has been director of the Clinic for Gynecology and Obstetrics at the University Hospital Giessen .

Meinhold-Heerlein has been a founding member and chairman of the non-profit Landesjugendorchester-Förderkreis e. V. Rhineland-Palatinate.

Scientific achievement

At the beginning of his scientific career Meinhold-Heerlein devoted himself together with John C. Reed at The Burnham Institute (La Jolla / USA) to overcoming chemotherapy and apoptosis resistance of ovarian cancer . Key factors of the two main apoptosis signaling pathways - the death receptor and the mitochondrial signaling pathway - were examined. Since both signal pathways are transactivated by the p53 known as the cell cycle regulator, analyzes of the p53 mutation and expression status were carried out in further work . With these analyzes it could be shown that in particular low-grade differentiated ovarian carcinomas have far more p53 mutations than originally assumed. In cooperation with Garret Hampton , Meinhold-Heerlein identified new molecular markers with the help of chip analyzes ( oligonucleotide arrays) that are suitable as therapeutic targets for various tumor subgroups or as serum markers for early detection. The focus was on the investigation of serous tumors, which make up the majority of malignant ovarian tumors. A key finding from this work was that non-invasive ovarian borderline tumors exhibited an almost identical molecular expression pattern to highly differentiated invasive ovarian carcinomas. In comparison, the moderately and slightly differentiated carcinomas exhibited a significantly different pattern. Meinhold thus made a contribution to today's understanding of serous ovarian cancer, in which only two fundamentally different disease types are distinguished: the low-grade carcinoma, which can develop from a benign cystadenoma and a borderline tumor, and the high-grade cancer. Carcinoma, the pathogenesis of which has not been conclusively clarified. After returning to Germany at the University of Kiel, he continued the molecular examinations of ovarian cancer as part of a Max Eder project of the German Cancer Aid and, together with Dirk Bauerschlag and Garret Hampton's group , identified other new markers that could be used as therapeutic targets or could be suitable for monitoring the course of therapy or for early detection. In collaboration with Ahmad Hussain and Stefan Barth (University of Cape Town / South Africa), he has recently devoted himself to immunological approaches for the detection and treatment of ovarian cancer and endometriosis at RWTH Aachen University. Within the framework of these theranostic approaches, molecules coupled to antibodies are examined for their diagnostic or therapeutic suitability.

Membership in international scientific associations

  • Organ Commission Ovary of the Gynecological Oncology Working Group (AGO)
  • Translational Research Commission of the Gynecological Oncology Working Group (AGO)
  • Scientific advisory board of the Endometriosis Research Foundation
  • Editorial Board BioMedRes International
  • Associate Editor Archives Gynecology and Obstetrics
  • Section Editor Current Obstetrics and Gynecology Reports

honors and awards

  • 2003: Staude Pfannenstiel Prize of the North German Society for Gynecology and Obstetrics
  • 2004: Science Award of the North German Society for Gynecology and Obstetrics
  • 2004: 1st prize from the German Society for Gynecology and Obstetrics
  • 2006: Lecture award from the North German Society for Gynecology and Obstetrics
  • 2006: GebFra Prize of the German Society for Gynecology and Obstetrics
  • 2007: Lecture award of the Translational Research Commission of the Gynecological Oncology Working Group (AGO)
  • 2008: Hans Frangenheim Prize of the Gynecological Endoscopy Working Group (AGE)
  • 2010: Dr. Rockstroh Prize of the German Society for Gynecology and Obstetrics

Publications

Web links

Individual evidence

  1. ↑ University women's clinic under new management. April 9, 2018, accessed June 30, 2019 .
  2. ↑ a b c Meinhold-Heerlein CV  ( page no longer available , search in web archives )  Info: The link was automatically marked as defective. Please check the link according to the instructions and then remove this notice. (PDF).@1@ 2Template: Dead Link / www.ukaachen.de  
  3. ^ Förderkreis eV Landesjugendorchester Rheinland-Pfalz LJO-Förderkreis eV
  4. ^ A b I. Meinhold-Heerlein, F. Stenner-Liewen, H. Liewen, S. Kitada, M. Krajewska, S. Krajewski, JM Zapata, A. Monks, DA Scudiero, T. Bauknecht, JC Reed: Expression and potential role of Fas-Associated Phosphatase-1 in Ovarian Cancer. In: Am J Pathol. 158, No. 4, 2001, pp. 1335-1344.
  5. ↑ M. Krajewska, JM Zapata, I. Meinhold-Heerlein, H. Hedayat, A. Monks, A. Shabaik, L. Bubendorf, OP Kallioniemi, H. Kim, G. Reifenberger, S. Krajewski, JC Reed: Expression of Bcl-2 family member bid in normal and malignant tissues. In: Neoplasia. 4, No. 2, 2002, pp. 129-140.
  6. ^ I. Meinhold-Heerlein, E. Ninci, H. Ikenberg, T. Brandstetter, I. Schwenk, A. Straub, B. Schmitt, H. Bettendorf, C. Ihling, R. Iggo, T. Bauknecht: Evaluation of methods to detect p53 mutations in ovarian cancer. In: Oncology. 60, No. 2, 2001, pp. 176-188.
  7. ^ I. Meinhold-Heerlein, D. Bauerschlag, F. Hilpert, P. Dimitrov, L. Sapinoso, M. Orlowska-Volk, T. Bauknecht, TW. Park, W. Jonat, A. Jacobsen, J. Sehouli, M. Krajewska, S. Krajewski, JC Reed, N. Arnold, GM Hampton: Molecular and prognostic distinction between serous ovarian tumors of low and high malignant potential. In: Oncogene. 24, No. 6, 2005, pp. 1053-1065.
  8. ↑ I. Meinhold-Heerlein, D. Bauerschlag, Y. Zhou, LM Sapinoso, K. Ching, H. Frierson jr., K. Bräutigam, J. Sehouli, E. Stickeler, D. Könsgen, F. Hilpert, C. von Kaisenberg, J. Pfisterer, T. Bauknecht, Jonat W, Arnold N, Hampton GM: An integrated clinical-genomics approach identifies a candidate multi-analyte blood test for serous ovarian carcinoma. In: Clin Cancer Res. 13, No. 2, 2007, pp. 658-666.
  9. ^ DO Bauerschlag, N. Maass, P. Leonhardt, FA Verburg, U. Pecks, F. Zeppernick, A. Morgenroth, F. Mottaghy, R. Tolba, I. Meinhold-Heerlein *, K. Bräutigam *: Fatty Acid Synthase Overexpression: Target for Therapy and Reversal of Chemoresistance in Ovarian Cancer. In: J Transl Med. 13, 2015, p. 146 * co-directed this study.
  10. ↑ K. Bräutigam, J. Biernath-Wüpping, DO Bauerschlag, CS von Kaisenberg, N. Arnold, W. Jonat, N. Maass, I. Meinhold-Heerlein: Combined treatment with TRAIL and PPARγ ligands overcomes chemoresistance of ovarian cancer cell lines . In: J Cancer Res Clin Oncol. 137, No. 5, 2010, pp. 875-886.
  11. ↑ DO Bauerschlag *, I. Meinhold-Heerlein *, A. Bleilevens, K. Bräutigam, W. Al Rawashdeh, S. Di Fiore, AM Haugg, F. Gremse, J. Steitz, N. Maass, R. Fischer, E Stickeler, S. Barth, AF Hussain: Detection and specific elimination of EGFR + ovarian cancer cells using a near infrared photoimmunotheranostic approach. In: Pharm Res J 34, No. 4, 2017, pp. 696-703 * contributed equally to this study.
  12. ^ German Society for Gynecology and Obstetrics: Awards Ceremonies at the DGGG Congress 2010 (PDF).
personal data
SURNAME Meinhold-Heerlein, Ivo
BRIEF DESCRIPTION German gynecologist
DATE OF BIRTH March 23, 1969
PLACE OF BIRTH Mainz